Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the rates for prescription drug user fees for fiscal year (FY) 2007. The Federal Food, Drug, and Cosmetic Act, as amended by the Prescription Drug User Fee Amendments of 2002 (Title 5 of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (PDUFA III)), authorizes FDA to collect user fees for certain applications for approval of drug and biological products, on establishments where the products are made, and on such products. Base revenue amounts for application fees, establishment fees, and product fees for FY 2007 were established by PDUFA III. Fees for applications, establishments, and products are to be established each year by FDA so that revenues from each category will approximate the revenue levels established in the statute, after those amounts have been first adjusted for inflation and workload. This notice establishes fee rates for FY 2007 for application fees for an application requiring clinical data ($896,200), for an application not requiring clinical data or a supplement requiring clinical data ($448,100), for establishment fees ($313,100), and for product fees ($49,750). These fees are effective on October 1, 2006, and will remain in effect through September 30, 2007. For applications and supplements that are submitted on or after October 1, 2006, the new fee schedule must be used. Invoices for establishment and product fees for FY 2007 will be issued in August 2006, using the new fee schedule.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Frank Claunts, Office of Management (HFA-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4427.End Further Info End Preamble Start Supplemental Information
The FFDCA, sections 735 and 736 (21 U.S.C. 379g and h), establishes three different kinds of user fees. Fees are assessed on the following: (1) Certain types of applications and supplements for approval of drug and biological products, (2) certain establishments where such products are made, and (3) certain products (21 U.S.C. 379h(a)). When certain conditions are met, FDA may waive or reduce fees (21 U.S.C. 379h(d)).
For FY 2003 through FY 2007, base revenue amounts for application fees, establishment fees, and product fees are established by PDUFA III. Base revenue amounts established for years after FY 2003 are subject to adjustment for inflation and workload. Fees for applications, establishments, and products are to be established each year by FDA so that revenues from each category will approximate the revenue levels established in the statute, after those amounts have been first adjusted for inflation and workload. The revenue levels established by PDUFA III continue the arrangement under which one-third of the total user fee revenue is projected to come from each of the three types of fees: Application fees, establishment fees, and product fees.
This notice establishes fee rates for FY 2007 for application, establishment, and product fees. These fees are effective on October 1, 2006, and will remain in effect through September 30, 2007.
II. Revenue Amounts for FY 2007, and Adjustments for Inflation and Workload
A. Statutory Fee Revenue Amounts
PDUFA III specifies that the fee revenue amount for FY 2007 for application fees is $86,434,000 and for both product and establishment fees is $86,433,000, for a total of $259,300,000 from all three categories of fees (21 U.S.C. 379h(b), before any adjustments are made.Start Printed Page 43781
B. Inflation Adjustment to Fee Revenue Amount
PDUFA III provides that fee revenue amounts for each FY after 2003 shall be adjusted for inflation. The adjustment must reflect the greater of the following amounts: (1) The total percentage change that occurred in the Consumer Price Index (CPI) (all items; U.S. city average) during the 12-month period ending June 30 preceding the FY for which fees are being set or (2) the total percentage pay change for the previous FY for Federal employees stationed in the Washington, DC metropolitan area. PDUFA III provides for this annual adjustment to be cumulative and compounded annually after FY 2003 (see 21 U.S.C. 379h(c)(1)).
The inflation increase for FY 2004 was 4.27 percent. This was the greater of the CPI increase during the 12-month period ending June 30 preceding the FY for which fees were being set (June 30, 2003—which was 2.11 percent) or the increase in pay for the previous FY (2003 in this case) for Federal employees stationed in the Washington, DC metropolitan area (4.27 percent).
The inflation increase for FY 2005 was 4.42 percent. This was the greater of the CPI increase during the 12-month period ending June 30 preceding the FY for which fees were being set (June 30, 2004—which was 3.27 percent) or the increase in pay for the previous FY (2004 in this case) for Federal employees stationed in the Washington, DC metropolitan area (4.42 percent).
The inflation adjustment for FY 2006 was 3.71 percent. This is the greater of the CPI increase during the 12-month period ending June 30 preceding the FY for which fees are being set (June 30, 2005—which was 2.53 percent) or the increase in pay for FY 2005 for Federal employees stationed in Washington, DC (3.71 percent).
The inflation adjustment for FY 2007 is 4.32 percent. This is the greater of the CPI increase during the 12-month period ending June 30 preceding the FY for which fees are being set (June 30, 2006—which is 4.32 percent) or the increase in pay for FY 2006 for Federal employees stationed in Washington, DC (3.44 percent).
Compounding these amounts (1.0427 x 1.0442 x 1.0371 x 1.0432) yields a total compounded inflation adjustment of 17.80 percent for FY 2007.
The inflation adjustment for each category of fees for FY 2007 is the statutory fee amount increased by 17.80 percent, the inflation adjuster for FY 2007. The FY 2007 inflation-adjusted revenue amount for application fees is $101,819,252 ($86,434,000 x 1.1780). For both product and establishment fees the inflation-adjusted revenue amount is $101,818,074 each ($86,433,000 x 1.1780). The total inflation-adjusted fee revenue amount for all three fee categories combined is $305,455,400 in FY 2007.
C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount
For each FY beginning in FY 2004, PDUFA III provides that fee revenue amounts, after they have been adjusted for inflation, shall be further adjusted to reflect changes in workload for the process for the review of human drug applications (see 21 U.S.C. 379h(c)(2)).
The conference report accompanying PDUFA III, House of Representatives Report number 107-481, provides guidance on how the workload adjustment provision of PDUFA III is to be implemented. Following that guidance, FDA calculated the average number of each of the four types of applications specified in the workload adjustment provision (human drug applications, commercial investigational new drug applications, efficacy supplements, and manufacturing supplements) received over the 5-year period that ended on June 30, 2002 (base years), and the average number of each of these types of applications over the most recent 5-year period that ended June 30, 2006.
The results of these calculations are presented in the first two columns of table 1 of this document. Column 3 reflects the average percent change in workload over the two 5-year periods. Column 4 shows the weighting factor for each type of application, estimating how much of the total FDA drug review workload was accounted for by each type of application in the table during the most recent 5 years. Column 5 of table 1 is the weighted percent change in each category of workload. This was derived by multiplying the weighting factor in each line in column 4 by the percent change from the base years in column 3. At the bottom right of the table the sum of the values in column 5 is added, reflecting a total increase in workload of 6.3 percent for FY 2007 when compared to the base years.
|Application Type||Column 1 5-Year Average Base Years||Column 2 Latest 5-Year Average||Column 3 Percent Change||Column 4 Weighting Factor||Column 5 Weighted Percent Change|
|FY 2007 workload adjuster||6.30%|
Increasing the inflation-adjusted revenue amount for application fees of $101,819,252 by the FY 2007 workload adjuster (6.3 percent) results in an increase of $6,414,613, for a total inflation and workload adjusted application fee revenue amount of $108,233,865. Increasing the inflation-adjusted revenue amount for establishment and product fees, each of which is $101,818,074, by the FY 2007 workload adjuster (6.3 percent) results in an increase of $6,414,539, for a total inflation and workload adjusted application fee revenue amount of $108,232,613 for each category. The total FY 2007 inflation and workload adjusted fee revenue target for all three fee categories combined is $324,699,091.
III. Adjustment for Excess Collections in Previous Years
Under the provisions of PDUFA, as amended, if the agency collects more fees than were provided for in appropriations in any year after 1997, FDA is required to reduce its Start Printed Page 43782anticipated fee collections in a subsequent year by that amount (21 U.S.C. 379h(g)(4)).
In FY 1998, Congress appropriated a total of $117,122,000 to FDA in PDUFA fee revenue. As of September 30, 2005, collections for FY 1998 totaled $117,849,016—or $727,016 in excess of the appropriation limit. Also, in FY 2004 Congress appropriated a total of $249,825,000 to FDA in PDUFA fee revenue, and FDA collected a total of $257,055,606 as of September 30, 2005. This is $7,230,906 in excess of appropriations. The total in excess collections for the 2 years is $7,957,922. These are the only fiscal years since 1997 in which FDA has collected more in PDUFA fees than Congress appropriated.
The total of $7,957,922 will be offset against FY 2007 revenue collections, lowering the net amount that would otherwise be collected. One-third of this amount, or $1,985,974, will be subtracted from the FY 2007 adjusted revenue amount for each fee category in the previous section. Thus, after adjustment for prior-year excess collections, the adjusted FY 2007 revenue target for each fee category is as follows:
- Application fee revenue amount: $105,581,224 ($108,233,865 - $2,652,641)
- Establishment fee revenue amount: $105,579,972 ($108,232,613 - $2,652,641)
- Product fee revenue amount: $105,579,973 ($108,232,613 - $2,652,640)
Thus, the adjusted revenue amount from all three categories after this adjustment totals $316,741,167.
IV. Final Year Adjustment
Under the provisions of PDUFA, as amended, the Secretary may, in addition to the inflation and workload adjustments, further increase the fees and fee revenues if such an adjustment is necessary to provide for not more than 3 months of operating reserves of carryover user fees for the process for the review of human drug applications for the first 3 months of FY 2008. The rationale for the amount of this increase shall be contained in the annual notice establishing fee revenues and fees for FY 2007 (21 U.S.C. 379h(c)(3)).
As of June 30, 2006, FDA has unallocated cash carryover balances of $42,777,720. In addition, the agency is estimating that application fees over the final 3 months of FY 2006 will add another $18,500,000 to this balance, for an estimated cash carryover of $61,277,720 on September 20, 2006.
In FY 2007, FDA expects to collect a total of $316,741,167 after adjustments, as noted at the end of section III of this document. To sustain current operations in FY 2007, FDA expects to obligate a total of $327 million (compared with anticipated obligations in FY 2006 of about $314,500,000). The anticipated obligations of $327 million will be about $10,259,000 more than anticipated collections. This will reduce the estimated carry-over balance over the course of FY 2007 from $61,278,000 to an estimated $51,019,000 ($61,278,000 - $10,259,000).
To sustain operations supported from user fees for the first 3 months of FY 2008, FDA estimates that it will need one-fourth of the $327 million it expects to spend in FY 2007, or $81,750,000. However, this amount will need to be increased for inflation by an estimated 5.8 percent (the average amount by which FDA's costs per FTE have increased over the past 5 years). The amount needed to sustain operations for the first 3 months of FY 2008 is thus estimated at $86,491,500, while the estimated carry-over balance at the beginning of FY 2008 is estimated at only $51,019,000. Thus, FDA will need an additional $35,472,500 as the final year adjustment to assure sufficient operating reserves for the first 3 months of FY 2008. One-third of this amount, rounded to the nearest thousand, or $11,824,000, will be added to the FY 2007 adjusted revenue amount for each fee category in the previous section. Thus, after the final-year adjustment, the adjusted FY 2007 revenue target for each fee category is as follows:
- Application fee revenue amount: $117,405,224 ($105,581,224 + $11,824,000)
- Establishment fee revenue amount: $117,403,972 ($105,579,972 + $11,824,000)
- Product fee revenue amount: $117,403,973 ($105,579,973 + $11,824,000)
Thus, after the final year adjustment, the adjusted FY 2007 revenue target from all fee types combined totals $352,141,167.
V. Application Fee Calculations
PDUFA III provides that the rates for application, product, and establishment fees be established 60 days before the beginning of each FY (21 U.S.C. 379h(c)(4)). The fees are to be established so that they will generate the fee revenue amounts specified in the statute, as adjusted for inflation and workload.
A. Application Fee Revenues and Application Fees
The application fee revenue amount that PDUFA III established for FY 2007 is $117,381,224, as calculated in the previous section. Application fees will be set to generate this amount.
B. Estimate of Number of Fee-Paying Applications and Establishment of Application Fees
For FY 2003 through FY 2007, FDA will estimate the total number of fee-paying full application equivalents (FAEs) it expects to receive the next FY by averaging the number of fee-paying FAEs received in the five most recent FYs. This use of the rolling average of the five most recent FYs is the same method that was applied in making the workload adjustment.
In estimating the number of fee-paying FAEs that FDA will receive in FY 2007, the 5-year rolling average for the most recent 5 years will be based on actual counts of fee-paying FAEs received for FY 2002 through FY 2006. For FY 2006, FDA is estimating the number of fee-paying FAEs for the full year based on the actual count for the first 9 months and estimating the number for the final 3 months.
Table 2 of this document shows, in column 1, the total number of each type of FAE received in the first 9 months of FY 2006, whether fees were paid or not. Column 2 shows the number of FAEs for which fees were waived or exempted during this period, and column 3 shows the number of fee-paying FAEs received through June 30, 2006. Column 4 estimates the 12-month total fee-paying FAEs for FY 2006 based on the applications received through June 30, 2006. All of the counts are in FAEs. A full application requiring clinical data counts as one FAE. An application not requiring clinical data counts as one-half an FAE, as does a supplement requiring clinical data. An application that is withdrawn, or refused for filing, counts as one-fourth of an FAE if it initially paid a full application fee, or one-eighth of an FAE if it initially paid one-half of the full application fee amount.Start Printed Page 43783
|Application or Action||Column 1 Total Received Through June 30, 2006||Column 2 Fee Exempt or Waived Through June 30, 2006||Column 3 Total Fee Paying Through June 30, 2006||Column 4 12-Month Fee-Paying Projection|
|Applications requiring clinical data||72.25||21.25||51||68|
|Applications not requiring clinical data||7.5||3.5||4||5.33|
|Supplements requiring clinical data||60.25||13.75||46.5||62|
|Withdrawn or refused to file||1||0||1||1.33|
In the first 9 months of FY 2006, FDA received 141 FAEs, of which 102.5 were fee-paying. Based on data from the last 7 FYs, on average, 25 percent of the applications submitted each year come in the final 3 months. Dividing 102.5 by 3 and multiplying by 4 extrapolates the amount to the full 12 months of the FY and projects the number of fee-paying FAEs in FY 2006 at 136.7.
All pediatric supplements, which had been exempt from fees prior to January 4, 2002, were required to pay fees effective January 4, 2002. This is the result of section 5 of the Best Pharmaceuticals for Children Act that repealed the fee exemption for pediatric supplements effective January 4, 2002. Thus, in estimating FY 2006 fee-paying receipts we must include in our calculations all the pediatric supplements submitted in the past 5 years that were previously exempt from fees prior to January 4, 2002. The exempted number of FAEs for pediatric supplements for FY 2002 was 4.5. Because fees on these supplements are paid for pediatric applications submitted in FY 2003 and beyond, the number of pediatric supplement FAEs exempted from fees in FY 2002 (the last year in table 3 of this document when fees were exempted) are added to the total of fee-paying FAEs received each year.
As table 3 of this document shows, the average number of fee-paying FAEs received annually in the most recent 5-year period, assuming all pediatric supplements had paid fees, and including our estimate for FY 2006, is 131 FAEs. FDA will set fees for FY 2007 based on this estimate as the number of full application equivalents that will pay fees.
|Exempt pediatric supplement FAEs||4.5||0||0||0||0||0.9|
The FY 2007 application fee is estimated by dividing the average number of full applications that paid fees over the latest 5 years, 131, into the fee revenue amount to be derived from application fees in FY 2007, $117,405,224. The result, rounded to the nearest $100, is a fee of $896,200 per full application requiring clinical data, and $448,100 per application not requiring clinical data or per supplement requiring clinical data.
VI. Fee Calculations for Establishment and Product Fees
A. Establishment Fees
At the beginning of FY 2006, the establishment fee was based on an estimate that 375 establishments would be subject to, and would pay, fees. By the end of FY 2006, FDA estimates that applicants have been billed for 400 establishment fees, before all decisions on requests for waivers or reductions are made. As in previous years, FDA again estimates that a total of 25 establishment fee waivers or reductions will be made for FY 2006, for a net of 375 fee-paying establishments. FDA will use this same number again, 375, for its FY 2007 estimate of establishments paying fees, after taking waivers and reductions into account. The fee per establishment is determined by dividing the adjusted total fee revenue to be derived from establishments ($117,403,972) by the estimated 375 establishments, for an establishment fee rate for FY 2006 of $313,100 (rounded to the nearest $100).
B. Product Fees
At the beginning of FY 2006, the product fee was based on an estimate that 2,350 products would be subject to and pay product fees. By the end of FY 2006, FDA estimates that 2,400 products will have been billed for product fees, before all decisions on requests for waivers or reductions are made. Assuming that there will be about 40 waivers and reductions granted, FDA estimates that 2,360 products will qualify for product fees in FY 2006, after allowing for waivers and reductions, and will use this number for its FY 2007 estimate. Accordingly, the FY 2007 product fee rate is determined by dividing the adjusted total fee revenue to be derived from product fees ($117,403,973) by the estimated 2,360 products for a FY 2007 product fee of $49,750 (rounded to the nearest $10).
VII. Fee Schedule for FY 2007
The fee rates for FY 2007 are set out in table 4 of this document:Start Printed Page 43784
|FEE CATEGORY||FEE RATES FOR FY 2007|
|Requiring clinical data||$896,200|
|Not requiring clinical data||$448,100|
|Supplements requiring clinical data||$448,100|
VIII. Implementation of Adjusted Fee Schedule
A. Application Fees
The appropriate application fee established in the new fee schedule must be paid for any application or supplement subject to fees under PDUFA that is received after September 30, 2006. Payment must be made in U.S. currency by check, bank draft, or U.S. postal money order payable to the order of the Food and Drug Administration. Please include the user fee ID number on your check. Your payment can be mailed to: Food and Drug Administration, P.O. Box 360909, Mellon Client Service Center, 500 Ross St., rm. 670, Pittsburgh, PA 15251-6909.
If checks are to be sent by a courier that requests a street address, the courier can deliver the checks to: Food and Drug Administration (360909), Mellon Client Service Center, 500 Ross St., rm. 670, Pittsburgh, PA 15262-0001. (Note: This Mellon Bank address is for courier delivery only.)
Please make sure that the FDA post office box number (P.O. Box 360909) is written on the check. The tax identification number of the Food and Drug Administration is 530 19 6965.
B. Establishment and Product Fees
By August 31, 2006, FDA will issue invoices for establishment and product fees for FY 2007 under the new fee schedule. Payment will be due on October 1, 2006. FDA will issue invoices in October 2007 for any products and establishments subject to fees for FY 2007 that qualify for fees after the August 2006 billing.Start Signature
Dated: July 26, 2006.
Assistant Commissioner for Policy.
[FR Doc. E6-12397 Filed 8-1-06; 8:45 am]
BILLING CODE 4160-01-S